Board of Directors
Mr. Mark Beaudet
Mark Beaudet is a co-founder of Paladin Labs Inc., a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products, that was acquired by Endo International plc in 2014 for approximately $3.0 billion. Since Paladin’s founding in 1996, Mr. Beaudet served as a member of the board of directors and as the company’s Vice President of Sales and Marketing until 2011 when he became interim President and CEO. Following Endo’s acquisition of Paladin, Mr. Beaudet joined the Endo International plc. executive leadership team and continued to lead the Paladin team.
Mr. Beaudet is a member of the board of directors of the McGill University Health Center Foundation, Loyola High School and the Loyola High School Foundation.
Mr. Beaudet also serves on the board of Altus Formulation Inc., a privately held drug formulation and development company. He is a former member of the board and former Chair of the Regulatory Affairs Committee of Innovative Medicines Canada (formerly Rx&D – Canada’s Research Based Pharmaceutical Industry Association). In 2015 Mr. Beaudet was inducted into the Canadian Healthcare Marketing Hall of Fame.
Dr. Damon Smith
Founder and CEO
Damon Smith has over thirty years of international experience in the biopharmaceutical sector specializing in the transformation of early stage companies into market or exit ready organizations. During his career Damon has held leadership positions at Therapeutic Antibodies Inc.. Conjuchem Inc and Labopharm Inc. where he served as Senior Vice President R&D. During this period Dr. Smith participated in three successful IPO (raising over $400MM) numerous successful financings and the launch of 7 new products in multiple markets. In 2012 Dr. Smith founded Altus Formulation Inc where he has served as CEO for the past 8 years scaling the company and leading it to commercialization readiness via its international large pharma partners.
Along with Dr. Chamberland, Dr. Smith is a Founder of TALLC.
Dr. Guy Chamberland
Guy Chamberland, M.Sc., Ph.D., Master Herbalist, has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Scientific Officer since October 15, 2018. He held the positions of Interim Chief Executive Officer and Chief Scientific Officer respectively since April 2018 and June 2016. Dr. Chamberland’s extensive experience in both executive and scientific roles establish him as an expert in the biopharmaceutical space. Dr. Chamberland has more than two decades of experience in drug development for the North American pharmaceutical industry with specific expertise in regulatory affairs, and the development and management of clinical research protocols and clinical studies for botanical medicines. He was also a member of the investment committee of the venture capital fund, Fonds Bionvation, for 7 years.
Along with Dr. Smith and Dr. Kelly, Dr. Chamberland is a Founder of TALLC.
Mr. Sylvain Guenette
Mr. Steeve Neron
Dr. Aurelia De Pauw
TALLC issues new Corporate Presentation
Dr. Damon Smith at Biotech Show Case
TALLC at the Ophthalmology Innovation Summit
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
© TALLC Inc. 2020